MOUNTAIN VIEW, Calif.,
Feb. 16, 2021 /PRNewswire/
-- AliveCor, the leader in AI-based personal ECG
technology and provider of enterprise cardiology solutions, today
announced a new collaboration with AstraZeneca (LSE/STO/Nasdaq:
AZN), a global science-led biopharmaceutical company, to research
new disease management solutions in cardiovascular, renal, and
metabolism (CVRM) therapeutic areas. The collaboration will
translate AliveCor's potassium detection technology and science,
which enables potassium measurement outside of blood draws, into
real-world disease management applications and solutions.
The cross-industry collaboration expands the research and
development of AliveCor's Kardia-K AI platform, which received
"Breakthrough Device Designation" status from the FDA to screen for
elevated levels of blood potassium. Kardia-K is being built using
AliveCor's proprietary deep neural network, and analyzes
electrocardiograms (ECGs) to measure a patient's potassium levels
without requiring any blood from the patient. AliveCor's neural
network was trained in collaboration with Mayo Clinic using more
than 1.5 million ECGs and was validated on approximately 62,000
ECGs. The research was published in JAMA Cardiology in April 2019.
"By collaborating across industries, AliveCor is leading the way
in the development of non- invasive, more accessible medical
solutions for patients and health organizations worldwide," said
Aman Bhatti, Head of BioPharma
Relationships at AliveCor. "Our collaboration with AstraZeneca
exemplifies how pharmaceutical and digital health companies can
work together to drive the future of medicine."
For the nearly 30 million U.S. adults with chronic kidney
disease, the one-day likelihood of a fatality is 3 to 13 times
higher if potassium is elevated. The current standard practice for
measuring potassium levels is a blood test, which is invasive,
inconvenient, and poses safety risks for patients during the
pandemic. A remote, easy-to-use potassium test could help track for
increased potassium levels in those patients, as well as the
500,000 Americans with end stage kidney disease and on dialysis,
where high potassium may contribute to up to 40% of fatalities.
The collaboration seeks to improve the delivery of life-changing
medicines that are fueling growth in the industry and providing
value to patients and society. Its initiative accelerates
AliveCor's work with key players in the BioPharma industry and
demonstrates diverse interest in AliveCor's technology, from
clinical research organizations to health systems to pharmaceutical
companies' digital therapeutic programs.
About AliveCor
AliveCor, Inc. is transforming
cardiological care using deep learning. The FDA-cleared
KardiaMobile device is the most clinically validated personal ECG
solution in the world. KardiaMobile provides instant detection of
Atrial Fibrillation, Bradycardia, Tachycardia, Sinus Rhythm with
Supraventricular Ectopy, Sinus Rhythm with Premature Ventricular
Contractions, Sinus Rhythm with Wide QRS and Normal Heart Rhythm in
an ECG. Kardia is the first AI-enabled platform to aid patients and
clinicians in the early detection of atrial fibrillation, the most
common arrhythmia and one associated with a highly-elevated risk of
stroke. AliveCor's enterprise platform allows third party providers
to manage their patients' and customers' heart conditions simply
and profitably using state-of-the-art tools that provide easy
front-end and back-end integration to AliveCor technologies.
AliveCor protects its customers with stringent data security
and compliance practices, achieving HIPAA compliance and SOC2 Type
1 and Type 2 attestations. AliveCor is a privately-held company
headquartered in Mountain View,
Calif. "Consumer" or "Personal" ECGs are ECG devices
available for direct sale to consumers. For more information,
visit alivecor.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/alivecor-announces-collaboration-with-astrazeneca-to-develop-non-invasive-potassium-monitoring-solutions-301228042.html
SOURCE AliveCor